Yonemitsu Y, Kaneda Y
Transport Unit, National Heart and Lung Institute, London, UK.
Methods Mol Med. 1999;30:295-306. doi: 10.1385/1-59259-247-3:295.
Since the first report of in vivo direct gene transfer to the vessel wall in 1990 (1) several vectors, such as adenovirus, liposomes, and adeno-associated virus have been employed to introduce foreign genes to the vascular tissue in vivo. Hemagglutinating virus of Japan (HVJ, Sendai virus), a member of the mouse paramyxovirus family, has been combined with liposomes to produce a novel gene transfer system, namely, HVJ liposomes (2,3). This vector system is constructed with inactivated viral particles and nonviral lamellar liposomes, and is defined as a "viral, nonviral hybrid vector." We and others have shown that this vector system can introduce foreign genes into the vascular tissue efficiently (4-9), and have also demonstrated that these genes and synthetic oligodeoxynucleotides (ODNs) transferred by this system could add some functions to the vessel wall (4-6) or prevent the vascular proliferative diseases (7-9).
自1990年首次报道体内直接基因转移至血管壁以来(1)，几种载体，如腺病毒、脂质体和腺相关病毒已被用于在体内将外源基因导入血管组织。日本血凝病毒(HVJ，仙台病毒)是小鼠副粘病毒家族的成员，已与脂质体结合以产生一种新型基因转移系统，即HVJ脂质体(2,3)。该载体系统由灭活的病毒颗粒和非病毒层状脂质体构建而成，并被定义为“病毒-非病毒杂交载体”。我们和其他人已经表明，该载体系统可以有效地将外源基因导入血管组织(4-9)，并且还证明了通过该系统转移的这些基因和合成寡脱氧核苷酸(ODN)可以为血管壁增添一些功能(4-6)或预防血管增殖性疾病(7-9)。
